Technology 27 of 266
Protein engineering
12 EIC Accelerator winners build on Protein engineering, 1% of the classified companies, in 1 sector and 3 industries.
12
Companies
1
Sectors
3
Industries
8
Countries
8%
Exits
33%
Show signs of scaling
Sectors
- Health12 (100%)
Industries
Used together with
Other technologies of the same companies
- Bacteriophages1
- Biomaterials1
- Gene editing1
- Microbial fermentation1
- Monoclonal antibodies1
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Protein engineering
Show the numbers
| Companies | Protein engineering | |
|---|---|---|
| 2019 | 3 | 3 |
| 2020 | 1 | 1 |
| 2021 | 3 | 3 |
| 2022 | 1 | 1 |
| 2023 | 3 | 3 |
| 2024 | 1 | 1 |
What happened to them (12 of 12 checked)
- Active10 (83%)
- Exit1 (8%)
- Failed0 (0%)
- Other1 (8%)
Signs of scaling
- Scaling4 (33%)
- Not scaling1 (8%)
- Scaling unclear7 (58%)
Countries
Keywords
- AI protein design
- ALS
- Anticoagulant reversal
- Antimicrobial resistance
- Beta-cell regeneration
- Biomanufacturing
- Bleeding
- Bone morphogenetic proteins
- Bone regeneration
- Canine antibodies
- Cell-free protein synthesis
- Chemotherapy-induced neuropathy
- Chronic wounds
- Coeliac disease
- Companion animals
- COVID-19
- Diabetes
- Eczema
- Emergency surgery
- Enzyme supplements
- Fracture nonunion
- Glaucoma
- Gluten digestion
- Gluten sensitivity
- Glyco-humanised antibodies
- Haematology
- Hearing loss
- Homeoproteins
- Inflammatory bowel disease
- MYC inhibition
- Neurodegeneration
- Neuropathic pain
- Neurotrophic factors
- Oncology
- Orthopaedic surgery
- Pancreatic cancer
- Pet health
- Phage display
- Pig farming
- Polyclonal antibodies
All 12 companies using Protein engineering
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODA | OSTEOforUNIONDrug solution for bone fracture nonunions | Biopharmaceuticals | Croatia | March 2024 | Blended finance | Active | Deep dive |
| SolasCure Limited | Aurase Wound GelLeveraging biomimicry and evidence-based medicine to treat patients with chronic wounds | Biopharmaceuticals | United Kingdom | June 2023 | Grant only | Active | Deep dive |
| DiogenX SAS | DiogenXBeta-cell recovery to counter diabetes | Biopharmaceuticals | France | March 2023 | Blended finance | Active | Deep dive |
| Nemysis Limited | Endoprotease 40 (E40)First ever preventive treatment for celiac disease and gluten sensitivity | Biopharmaceuticals | Ireland | January 2023 | Grant first | Active | Deep dive |
| Brainever | HOMEOBRAINHomeoproteins as novel therapies for neurodegenerative diseases | Biopharmaceuticals | France | March 2022 | Grant first | Active | Deep dive |
| ADIVO GMBH | CAESAR IBD ProjectThe CAESAR IBD Project: Developing Therapeutic Antibodies for Pets | Animal health | Germany | October 2021 | Blended finance | Acquired | Deep dive |
| Hoba Therapeutics ApS | Sense21HB-086 and HB-097 for treatment of chronic sensory neuronal disorders - neuropathic pain and hearing loss | Biopharmaceuticals | Denmark | June 2021 | Grant first | Active | Deep dive |
| VarmX BV | StopBleedingThe first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants. | Biopharmaceuticals | Netherlands | June 2021, October 2024 | Blended finance | Active | Deep dive |
| XENOTHERA | BRIGHTTreat severe cases of infection at COV with XAV-19 | Biopharmaceuticals | France | March 2020 | Grant only | Pivoted | Deep dive |
| LenioBio GmbH | PEPPERIndustrial-scale plant-based protein production in a cell-free platform | Life science tools | Germany | June 2019 | Grant only | Active | Deep dive |
| Micreos Human Health B.V. | StaphIMPACTSA.100: Next-generation targeted antibacterial product entering European market | Biopharmaceuticals | Netherlands | April 2019 | Grant only | Active | Deep dive |
| PEPTOMYC SL | MYCureInnovative cancer therapy through Myc inhibition: taking OMO-103 to market | Biopharmaceuticals | Spain | April 2019, June 2023 | Grant only | Active | Deep dive |